Search Results

Anokion SA today announced additional favorable safety and efficacy data from the company’s ongoing Phase 1b/2 clinical trial (ACeD-it) evaluating KAN-101 as a treatment for celiac disease.

Anokion SA announced today that Deborah Geraghty, Ph.D., president and chief executive officer, will participate in the BofA Healthcare Trailblazers Private Company Conference on Thursday, October 26, 2023, in Boston, Mass.

Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced a series of senior leadership promotions and a new senior appointment, effective immediately.

Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today reported progress for its clinical-stage programs, KAN-101 and ANK-700. The company’s lead product candidate, KAN-101, is being evaluated for the treatment of celiac disease, and its second candidate, ANK-700, is being evaluated for the treatment of multiple sclerosis (MS).

Anokion Announces Nature Biomedical Engineering Publication Further Validating its Immune Tolerance Approach to Treating Celiac Disease and Multiple Sclerosis.

Anokion SA today announced favorable new pharmacodynamic and pharmacokinetic data from the company’s completed Phase 1 clinical trial evaluating KAN-101 as a treatment for celiac disease.

Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that Pfizer has made a $35 million equity investment in Anokion through the Pfizer Breakthrough Growth Initiative.

Anokion SA announced that The Lancet Gastroenterology & Hepatology has published clinical data on KAN-101 from the Phase 1 ACeD Trial, which support the favorable safety of KAN-101 and signals of dose-dependent reactivity to gluten and induction of immune tolerance in patients with celiac disease.